KALA BIO, INC. Restricted Cash and Cash Equivalents
KALA BIO, INC. (KALA) had Restricted Cash and Cash Equivalents of $175.00 thousand as of 2023-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2024-05-14
- 2023-03-31: Restricted Cash and Cash Equivalents $175.00K.
- 2022-12-31: Restricted Cash and Cash Equivalents $250.00K.
- 2022-09-30: Restricted Cash and Cash Equivalents $250.00K.
- 2022-06-30: Restricted Cash and Cash Equivalents $700.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2023-03-31 | $175.00K 10-Q · filed 2024-05-14 |
| 2022-12-31 | $250.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $250.00K 10-Q · filed 2023-11-13 |
| 2022-06-30 | $700.00K 10-Q · filed 2023-08-04 |
| 2022-03-31 | $700.00K 10-Q · filed 2023-05-09 |
| 2021-12-31 | $2.74M 10-K · filed 2023-03-03 |
| 2021-09-30 | $2.74M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $2.74M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $12.49M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $12.49M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |